Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[11C]-PXT012253 PET Study in Healthy Subjects
NCT03826134Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Jan 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PXT-012253, sponsored by Lundbeck. Primary endpoints: Total distribution volumes up to 3 days and Binding potential up to 3 days. Started Jan 2019; status: completed.
02
Drugs
PXT-012253
Beyond the preview
Go deeper on NCT03826134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03826134.